BioPharmSignal logoBioPharmSignal

Biotech News

AtriCure to Announce Third Quarter 2026 Financial Results

AtriCure (ATRC)AtriCureEarnings

MASON, Ohio --(BUSINESS WIRE)--Oct. 13, 2026-- AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter

Related news

HYPRHyperfine2026-10-08 11:30 EST

Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026

IRMDiRadimed2026-10-23 12:30 EST

IRADIMED CORPORATION to Hold Third Quarter 2026 Financial Results Conference Call on October 30, 2026

TMCITreace Medical Concepts2026-10-23 11:05 EST

Treace to Report Third Quarter 2026 Financial Results on November 6, 2026

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

AORTArtivion2026-10-22 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results

PLSEPulse Biosciences2026-10-22 20:05 EST

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

DNLIDenali Therapeutics2026-10-22 20:01 EST

Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

APYXApyx Medical2026-10-22 12:00 EST

Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026

SGHTSight Sciences2026-10-21 20:05 EST

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

OMOutset Medical2026-10-21 20:05 EST

Outset Medical to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

View all latest news

AtriCure

Atrial Fibrillation Surgery AtriCure develops medical devices and procedures for the surgical treatment of atrial fibrillation. Its products are used by cardiac surgeons to create controlled lesions that interrupt abnormal electrical pathways and restore a more regular heart rhythm. Ablation Technologies The Isolator Synergy Ablation...

Recent company news

ATRCAtriCure2026-10-13 12:00 EST

AtriCure to Announce Third Quarter 2026 Financial Results

ATRCAtriCure2026-08-25 12:00 EST

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

ATRCAtriCure2026-07-27 12:00 EST

AtriCure to Participate at Upcoming Investor Conferences

ATRCAtriCure2026-07-23 20:01 EST

AtriCure Reports Second Quarter 2026 Financial Results

ATRCAtriCure2026-07-02 12:00 EST

AtriCure to Announce Second Quarter 2026 Financial Results

Stock data

Close
59.30 USD
Market cap
1.31B USD
Exchange
NASDAQ
Sector
MedTech
Location
United States